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Abstract
Background: Early treatment of aortic valve stenosis is recommended in eligible symptomatic patients with severe
aortic valve stenosis who would otherwise have a poor prognosis. The sutureless aortic valve bioprosthesis offers an
alternative to standard aortic valve replacement with a sutured valve, but limited data are available in patients who
have undergone multiple valve procedures involving the new, sutureless technology. We sought to investigate
outcomes in high operative risk patients with previous or concomitant valve surgery who were implanted with a
sutureless valve.
Methods: SURE-AVR is an ongoing, prospective, multinational registry of patients undergoing aortic valve
replacement. In-hospital and post-discharge outcomes up to 5 years were collected.
Results: The study population comprised 78 patients (mean ± SD: age 73.6 ± 7.6 years, logistic EuroSCORE 18.0 ±
17.5) enrolled at 13 sites who presented for concomitant or previous mitral valve repair (n = 45) or replacement
(n = 33), with or without additional concomitant procedures, and were implanted with a sutureless valve. Mean ±
SD overall aortic cross-clamp time was 109 ± 41 min and cardiopulmonary bypass time was 152 ± 49 min. Mean ±
SD aortic pressure gradients decreased from 37.6 ± 17.7 mmHg preoperatively to 13.0 ± 5.7 mmHg at hospital
discharge, and peak aortic pressure gradient from 61.5 ± 28.7 to 23.4 ± 10.6 mmHg. Early events included 1 death,
1 transient ischaemic attack, and 1 bleed (all 1.3%); a permanent pacemaker implantation was required in 6 patients
(7.7%), and 2 reoperations (not valve related) (2.6%) took place. Over a median follow-up of 55.5 months (Q1 13.4,
Q3 68.6), 12 patients died (6 cardiovascular and 6 non-cardiovascular, both 2.1% per patient-year). Five-year survival
was 81.3%. Late paravalvular leak occurred in 2 patients (0.7% per patient-year) and permanent pacemaker
implantation was required in 3 patients (0.1% per patient-year). There was no apparent rise in mean or peak aortic
pressure gradient over the study.
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Conclusions: These results suggest that the sutureless implant is a technically feasible procedure during mitral
surgery and is associated with good clinical outcomes.
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Background
Aortic valve stenosis is the most frequent valvular dis-
ease resulting in surgical or catheter intervention in
Western countries, and the prevalence is rising due to
the ageing population [1]. Early treatment is recom-
mended in eligible symptomatic patients with severe
aortic valve stenosis, who would otherwise have a poor
prognosis [1].
The sutureless aortic valve bioprosthesis offers an al-
ternative to standard aortic valve replacement (AVR)
with a sutured valve. It has a shorter cross-clamp time
than traditional valves, and hence a shorter myocardial
ischaemia time [2], and is associated with better clinical
outcomes and reduced hospital costs [3]. In a meta-
analysis involving 84 studies, reductions in aortic cross-
clamp and cardiopulmonary bypass times were reported
with the Perceval sutureless valve (LivaNova plc,
London, UK) versus a traditional sutured prosthesis.
Limited data, restricted to small, single-centre, short-
term cohorts, are available in patients who have under-
gone multiple valve procedures involving the new,
sutureless technology [4–8]. In elderly high-risk patients
with isolated AVR, rates of operative mortality range
from 0 to 3% for sutureless AVR and from 4 to 10% for
conventional AVR [2, 9–12]. However, higher rates have
been reported in patients undergoing complex concomi-
tant procedures (5.3–7.4% for sutureless AVR and 15.6%
for conventional AVR) [7, 13]. We therefore sought to
investigate early and late outcomes in high operative risk
patients with previous or concomitant valve surgery who
were implanted with the sutureless valve, using data
from the Sorin Universal REgistry on Aortic Valve
Replacement (SURE-AVR).
Patients and methods
SURE-AVR is an ongoing, prospective, observational
registry being conducted at 60 sites in 18 countries in
Europe, Canada, and Australia (ClinicalTrials.gov identi-
fier: NCT02679404). Patients implanted with any of the
commercially available LivaNova aortic products are eli-
gible for enrolment. This analysis focuses on patients
implanted with the Perceval sutureless aortic valve who
presented at 13 sites for concomitant or previous mitral
valve repair or replacement with or without additional
concomitant procedures.
The Perceval (LivaNova plc, London, UK) sutureless
valve is a self-anchoring, self-expanding, surgical aortic
bioprosthesis indicated for the replacement of damaged
or malfunctioning native aortic heart valves or pros-
theses. It has a functional component, comprising bovine
pericardium, stabilized in buffered glutaraldehyde solu-
tion, and a super-elastic metal alloy stent, which has the
dual role of valve support and anchoring to the aortic
root with no permanent sutures. Before implantation,
the prosthesis diameter is reduced to a suitable size for
loading onto a holder accessory. The valve is then posi-
tioned and released in the aortic root and post-dilated
using a balloon catheter. The device is available in 4
sizes (small, medium, large, extra-large, corresponding
to prosthesis heights of 31.0, 33.0, 35.5, and 37.5 mm, re-
spectively). Implantation could be performed using a
traditional surgical approach [14, 15] or through minim-
ally invasive cardiac surgery [16–18].
Patients were enrolled in a sequential and prospective
manner and were treated based on the standard of care
at participating sites. All patients received a unique
registry number in the electronic data capture system to
guarantee their anonymity. Participation was voluntary,
and patients could withdraw from participating at any
time.
Baseline data were entered into an electronic case re-
port form by trained study coordinators, and included
demographic, clinical, echocardiographic, and surgical
data. Follow-up visits were performed according to the
centres’ usual practices (by telephone call, referring
physician, or clinical visit) at 1 year and annually there-
after to 5 years, with follow-up at 7 and 10 years in se-
lected centres. The results presented herein are limited
to 5-year follow-up.
An electronic data capture system was used to allow
specific quality control checks. The sponsor’s project
team also applied checks to ensure an appropriate level
of quality and compliance of the data. No source verifi-
cation visits were conducted. Before enrolling patients,
staff at each participating centre underwent training on
the protocol, electronic case report form, and electronic
data capture system.
The design and conduct of the registry are overseen by a
study coordinating committee comprising representatives
from the different regions involved in the study. The com-
mittee is responsible for registry oversight, including study
progress, patient safety, and data quality and integrity.
Clinical outcomes
Data on multiple procedural and hospital discharge vari-
ables were collected, including implant success, cross-
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clamp time, length of stay in the intensive care unit, and
total length of hospitalization. Clinical success was de-
fined as a successful valve implantation without the oc-
currence of major adverse events by the time of
discharge. Major adverse events (investigator reported)
were defined as death (all-cause, non-cardiovascular, and
cardiovascular [including deaths of unknown cause]),
stroke, and reintervention (surgery or other cardiac inva-
sive therapy). Serious valve-related adverse events in-
cluded bleeding, thromboembolism, valve thrombosis,
endocarditis, non-structural dysfunction, and structural
valve deterioration. All adverse events are defined ac-
cording to the Valve Academic Research Consortium-2
criteria [19]. Severity of valve dysfunction was classified
as mild (grade 1+), moderate (2+), moderate to severe
(3+) or severe (4+). Improvement in clinical status was
defined as an improvement of ≥1 in the New York Heart
Association (NYHA) classification from baseline (before
the procedure), measured annually throughout the study.
Echocardiographic and haemodynamic data were col-
lected. Early outcomes were defined as those occurring
up to 30 days after the procedure and late outcomes as
those occurring > 30 days after the procedure.
Statistical analysis
Variables are described as mean ± standard deviation
(SD) or median (quartile [Q1, Q3]; range) for quantita-
tive variables and as number (%) for qualitative variables.
Outcomes are reported as descriptive statistics. The
rates of early adverse events were calculated as the num-
ber of events divided by the number of patients. Linear-
ized complication rates were calculated as the number of
late events divided by the number of patient-years. The
statistical analyses were performed using SAS® (Release
9.4, by SAS Institute Inc., Cary, NC, USA).
Results
A total of 1134 patients (482 men and 652 women) im-
planted with a sutureless valve were prospectively en-
rolled in the SURE-AVR registry between March 2011
and March 2019. Of these, 78 patients (enrolled at 13
sites) had undergone a previous and/or concomitant mi-
tral valve procedure: 45 mitral valve repair and 33 mitral
valve replacement.
The characteristics of the study population are detailed
in Table 1. Most patients were female (74.4%) and the
mean ± SD age at surgery was 73.6 ± 7.6 years. The main
indication for a sutureless implant was aortic valve sten-
osis (59.0%). A diagnosis of mitral regurgitation was re-
ported for 64.1% of the patients. Tricuspid regurgitation
was diagnosed in 61.5% of the patients. Most of the pa-
tients (87.0%) were in NYHA class II or III. Mean ± SD
logistic EuroSCORE I was 18.0 ± 17.5.
Before the sutureless implant, 11.5% of patients had
undergone aortic valve replacement, 11.5% mitral valve
replacement, 10.3% coronary artery bypass graft (CABG),
and 7.7% mitral valve repair (Table 2).
Surgical procedures
The majority (76.9%) of patients underwent a median
sternotomy approach and a large-size valve was im-
planted in 46.2% (Table 3). A concomitant procedure
was reported in 89.7% of the patients, with CABG per-
formed in 16.7% and tricuspid repair in 16.7%. The
sutureless valve was successfully implanted in all
patients.
Mean ± SD overall aortic cross-clamp time was 109 ±
41min (median 105, Q1 84, Q3 132 min) and the
mean ± SD cardiopulmonary bypass time was 152 ± 49
min (median 145, Q1 124, Q3 173 min) (Table 3). Mean
length of stay in the intensive care unit was 3.1 ± 4.1 days
(median 2.0, Q1 1.0, Q3 3.5 days); total length of hospital
stay was 14.2 ± 9.4 days (median 11.0, Q1 8.0, Q3 16.0
days).
Early outcomes
Mean ± SD effective orifice area was 0.7 ± 0.3 cm2 before
surgery and 1.4 ± 0.3 cm2 at discharge (Fig. 1). Mean aor-
tic pressure gradient decreased from 37.6 ± 17.7 mmHg
preoperatively to 13.0 ± 5.7 mmHg at discharge from
hospital, and peak aortic pressure gradient from 61.5 ±
28.7 mmHg to 23.4 ± 10.6 mmHg.
Early outcomes are detailed in Table 4. There was 1
death (due to septicaemia), 1 transient ischaemic attack,
and 1 case of bleeding (all 1.3%). There were no cases of
endocarditis, myocardial infarction, or structural valve
deterioration. Mild non-structural valve dysfunction (not
requiring intervention) was reported in 10 patients
(12.8%). Mild paravalvular leak occurred in 1 patient
(1.3%). A permanent pacemaker implantation was re-
quired in 6 patients (7.7%), due to third-degree atrioven-
tricular block in 4 patients and for unspecified
conduction disorders in 2 patients. Two reoperations
(not valve related) (2.6%) took place, 1 due to subtampo-
nade pericardial effusion and 1 to superior vena cava
syndrome. No explants were reported.
Late outcomes
Median study follow-up duration was 55.5 months (Q1
13.4, Q3 68.6 months), with a cumulative follow-up of
289.2 patient-years (including 282.5 patient-years). Late
outcomes are detailed in Table 4. Mean effective orifice
area was 1.4 ± 0.4 cm2, mean aortic pressure gradient
was 12.5 ± 6.0 mmHg, and peak aortic pressure gradient
was 21.4 ± 10.7 mmHg at 5 years (Fig. 1).
Six cardiovascular deaths (2.1% per patient-year) were
reported as late outcomes, 1 caused by worsening heart
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Table 1 Baseline demographics and clinical characteristics in overall population and according to type of mitral valve surgery
Characteristic Overall population (n = 78) Mitral repair (n = 45) Mitral replacement (n = 33)
Women, n (%) 58 (74.4) 31 (68.9) 27 (81.8)
Age at surgery (years), mean ± SD 73.6 ± 7.6 73.0 ± 8.3 74.5 ± 6.5
Range 55–88 55–88 60–87
Body surface area (m2), mean ± SD 1.7 ± 0.2 1.8 ± 0.2 1.7 ± 0.2
Diagnosis, n (%)
Aortic valve stenosis 46 (59.0) 28 (62.2) 18 (54.5)
Aortic steno-regurgitation 16 (20.5) 7 (15.6) 9 (27.3)
Aortic regurgitation 15 (19.2) 10 (22.2) 5 (15.2)
Mitral stenosis 7 (9.0) 3 (6.7) 4 (12.1)
Mitral steno-regurgitation 10 (12.8) 2 (4.4) 8 (24.2)
Mitral regurgitation 50 (64.1) 36 (80.0) 14 (42.4)
Tricuspid regurgitation (mild to severe) 48 (61.5) 28 (62.2) 20 (60.6)
Risk factors, n (%)
Diabetes mellitus 23 (29.5) 15 (33.3) 8 (24.2)
Coronary artery disease 28 (35.9) 16 (35.6) 12 (36.4)
Endocarditis 6 (7.7) 3 (6.7) 3 (9.1)
Renal insufficiency 12 (15.4) 7 (15.6) 5 (15.2)
Cerebrovascular events 4 (5.1) 4 (8.9) 0
Chronic lung disease 9 (11.5) 7 (15.6) 2 (6.1)
NYHA class (n = 77) (n = 45) (n = 32)
I 1 (1.3) 1 (2.2) 0
II 35 (45.5) 24 (53.3) 11 (34.4)
III 32 (41.6) 15 (33.3) 17 (53.1)
IV 9 (11.7) 5 (11.1) 4 (12.5)
Left ventricular ejection fraction (%) (n = 25) (n = 15) (n = 10)
Mean ± SD 53.1 ± 9.6 50.4 ± 8.8 57.0 ± 9.7
Median (quartile 1, quartile 3) 55.0 (45.4; 60.0) 53.7 (45.0; 57.0) 57.5 (50.0; 62.0)
Logistic EuroSCORE I (n = 50) (n = 29) (n = 21)
Mean ± SD 18.0 ± 17.5 15.9 ± 17.7 20.9 ± 17.3
Median (quartile 1, quartile 3) 11.5 (7.5; 21.5) 9.1 (6.6; 18.5) 15.7 (9.1; 24.4)
NYHA New York Heart Association, SD standard deviation
Table 2 Previous cardiac surgery in the overall population and according to type of mitral valve surgerya
Surgery, n (%) Overall population (n = 78) Mitral repair (n = 45) Mitral replacement (n = 33)
Coronary artery bypass graft 8 (10.3) 1 (2.2) 7 (21.2)
Repair procedure 10 (12.8) 5 (11.1) 5 (15.2)
Aortic valve repair 5 (6.4) 3 (6.7) 2 (6.1)
Mitral valve repair 6 (7.7) 3 (6.7) 3 (9.1)
With ring 3/6 (50.0) 2/3 (66.7) 1/3 (33.3)
Valve replacement 15 (19.2) 3 (6.7) 12 (36.4)
Aortic valve replacement 9 (11.5) 3 (6.7) 6 (18.2)
Mitral valve replacement 9 (11.5) 0 9 (27.3)
aSome patients may have undergone more than one previous cardiac surgery
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failure, 1 due to a possible cardiac cause, and 4 of an un-
known cause. Six non-cardiovascular deaths (2.1% per
patient-year) occurred, 3 as a result of neoplasia, 2 due
to other non − valve-related causes (1 urosepsis, 1 un-
known [the patient died while abroad and based on the
information provided, their doctor classified the death as
non-cardiovascular]), and 1 due to renal failure. Survival
at 5-year follow-up was 81.3% in the overall population,
83.8% in the mitral repair group, and 77.9% in the mitral
replacement group (Fig. 2). Two cases of bleeding (0.7%
per patient-year) and 1 case each of transient ischaemic
attack, non-disabling stroke, and endocarditis (all 0.4%
per patient-year) occurred. No cases of myocardial in-
farction, thrombosis, or structural valve deterioration
were reported. In addition to the 2 cases requiring re-
intervention described above, mild non-structural valve
dysfunction (intra-prosthetic regurgitation) was reported
in 9 patients (3.2% per patient-year), none of which re-
quired intervention. Paravalvular leak occurred in 2 pa-
tients (0.7% per patient-year) (mild regurgitation without
any haemodynamic consequences). Permanent pace-
maker implantation was required in 3 patients (1.1% per
patient-year), due to atrioventricular block III in 1 pa-
tient and other unspecified conduction disorders in 2
patients. A transcatheter valve (0.4% per patient-year)
was implanted in 1 patient after 873 days, due to moder-
ate/severe regurgitation. Two sutureless valves were
explanted (0.7% per patient-year), 1 due to endocarditis
and 1 to non-structural valve dysfunction. There was no
apparent rise in either the mean aortic or peak gradient
over the course of the study (Fig. 1).
Discussion
In this population of patients at high operative risk who
had undergone a previous and/or concomitant valvular
procedure, the sutureless biological aortic valve was a
technically feasible procedure during mitral surgery and
was associated with good clinical outcomes, both early
after the procedure and up to 5 years of follow-up. Im-
plantation of the sutureless aortic valve in the presence
Table 3 Procedural characteristics in the overall population and according to type of mitral valve surgery
Characteristic, n (%) Overall population (n = 78) Mitral repair (n = 45) Mitral replacement (n = 33)
Surgical approach
Median sternotomy 60 (76.9) 30 (66.7) 30 (90.9)
Minimally invasive cardiac surgery 18 (23.1) 15 (33.3) 3 (9.1)
Mini thoracotomy 17 (21.8) 15 (33.3) 2 (6.1)
Mini sternotomy 1 (1.3) 0 1 (3.0)
Valve size (aortic annulus diameter)
Small (19–21 mm) 9 (11.5) 5 (11.1) 4 (12.1)
Medium (21–23mm) 29 (37.2) 14 (31.1) 15 (45.5)
Large (23–25 mm) 36 (46.2) 23 (51.1) 13 (39.4)
Extra large (25–27 mm) 4 (5.1) 3 (6.7) 1 (3.0)
Concomitant procedures 70 (89.7) 42 (93.3) 28 (84.8)
CABG 13 (16.7) 11 (24.4) 2 (6.1)
Atrial fibrillation ablation 3 (3.8) 2 (4.4) 1 (3.0)
Mitral surgery 69 (88.5) 42 (93.3) 27 (81.8)
Repair procedure 43/69 (62.3) 42/42 (100.0) 1/27 (3.7)
Replacement procedure 26/69 (37.7) 0 26/27 (96.3)
Tricuspid surgery 13 (16.7) 6 (13.3) 7 (21.2)
Repair procedure 13/13 (100.0) 6/6 (100.0) 7/7 (100.0)
Replacement procedure 0 0 0
Implant successful 78 (100.0) 45 (100.0) 33 (100.0)
Cross-clamp time (min)
Mean ± SD 109 ± 41 107 ± 28 113 ± 55
Median (quartile 1, quartile 3) 105 (84; 132) 105 (85; 125) 106 (77; 136)
Cardiopulmonary bypass time (min)
Mean ± SD 152 ± 49 147 ± 32 159 ± 68
Median (quartile 1, quartile 3) 145 (121; 173) 141 (124; 168) 148 (118; 191)
CABG coronary artery bypass graft, SD standard deviation
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of a previously implanted prosthesis in the mitral pos-
ition or with a concomitant mitral valve procedure
appears to be a viable option.
Limited comparative data are currently available in pa-
tients undergoing multiple valve procedures with stented
or sutureless valves. One of the largest is the Epic study
[20], which enrolled an elderly all-comer population
undergoing aortic, mitral, or double-valve replacement
with a stented porcine xenograft during 2001 to 2012
and followed them for a mean ± SD of 4.5 ± 3.5 years. Of
2544 patients enrolled, 347 underwent mitral valve re-
placement, 27.6% of whom had undergone previous car-
diac surgery and 39.6% were undergoing additional
cardiac procedures. More recent studies are available,
comparing sutureless with conventional AVR in patients
undergoing concomitant cardiac procedures, or
reporting outcomes in patients undergoing isolated
sutureless AVR or with concomitant cardiac procedures,
but most are relatively small, retrospective in design,
have no comparator arm, or involve lower-risk patients
[7, 13, 21]. In the recently published prospective, ran-
domized PERSIST-AVR study [22], 910 patients with se-
vere symptomatic aortic valve stenosis were randomized
to undergo implantation with a sutureless valve or a
standard aortic valve, using a conventional or minimally
invasive approach. The study showed that in patients
undergoing isolated AVR or AVR plus CABG, the
sutureless valve reduced operative time and was nonin-
ferior to conventional bioprostheses for 1-year major
complications (a composite of all-cause death, myocar-
dial infarction, stroke, or valve reintervention). The rate
of concomitant surgical procedures in the PERSIST-
Fig. 1 a Effective orifice area and b mean aortic pressure gradient, preoperatively and up to 5 years of follow-up. Vertical lines indicate
standard error
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AVR study was, however, much lower than in our
present study (30% vs 89.7%, respectively),
Prolonged aortic cross-clamping during AVR is associ-
ated with higher mortality and morbidity in patients
undergoing cardiac surgery [23]. Flameng et al. [2], in a
population of 32 patients (median logistic EuroSCORE
9.99) requiring AVR with or without concomitant
CABG, reported that a sutureless stent-mounted aortic
valve could be implanted in less than 20min of aortic
cross-clamping, and in 23min for AVR plus CABG. In a
retrospective study of 314 patients undergoing AVR with
a sutureless bioprosthesis (29.9% of whom underwent
CABG), the mean ± SD aortic cross-clamp time was
39 ± 15 min for isolated AVR and 52 ± 26 min for AVR
with concomitant CABG [13]. Hanedan et al. [7]
reported longer operative times in their study of 70
high-risk elderly patients undergoing sutureless AVR
plus other cardiac procedures (76.3% of whom under-
went CABG), with a mean ± SD cross-clamp time of
78 ± 28 min and a cardiopulmonary bypass time of
119 ± 42min, both of which were statistically signifi-
cantly shorter than with conventional AVR using a su-
tured valve (122 ± 38min and 166 ± 50 min, respectively;
both P = 0.001). In the Epic study [20], the mean ± SD
aortic cross-clamp time was 84 ± 44min and the cardio-
pulmonary bypass time was 142 ± 60 min. The operative
times were longer in the present study (cross-clamp
109 ± 41 min and cardiopulmonary bypass 152 ± 49min),
reflecting the high rate of mitral (88.5%) and tricuspid
(16.7%) repair and replacement procedures in this
Table 4 Early and late adverse events in the overall population and according to type of mitral valve surgery
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(n = 33; 122.2
patient-years)
Death 1 (1.3) 0 1 (3.0) 12 (4.2) 6 (3.7) 6 (4.9)
Cardiovascular 0 0 0 6 (2.1) 3 (1.9) 3 (2.5)
Non-cardiovascular 1 (1.3)a 0 1 (3.0) 6 (2.1)b 3 (1.9) 3 (2.5)
Reintervention 2 (2.6) 0 2 (6.1) 4 (1.4) 3 (1.9) 1 (0.8)
Valve related 0 0 0 3 (1.1)c 2 (1.2) 1 (0.8)
Not valve related 2 (2.6) 0 2 (6.1) 1 (0.4) 1 (0.6) 0
Cerebrovascular accident 1 (1.3) 1 (2.2) 0 2 (0.7) 1 (0.6) 1 (0.8)
Stroke 0 0 0 1 (0.4)d 0 1 (0.8)
Transient ischaemic attack 1 (1.3) 1 (2.2) 0 1 (0.4) 1 (0.6) 0
Bleeding 1 (1.3) 0 1 (3.0) 2 (0.7) 2 (1.2) 0
Minore 0 0 0 1 (0.4) 1 (0.6) 0
Majorf 0 0 0 0 0 0
Not classified 1 (1.3) 0 1 (3.0) 1 (0.4) 1 (0.6) 0
Non-structural valve dysfunction 10 (12.8) 1 (2.2) 9 (27.3) 13 (4.6) 8 (5.0) 5 (4.1)
Intra-prosthetic regurgitation (1+) 6 (7.7) 0 6 (18.2) 9 (3.2) 6 (3.7) 3 (2.5)
Paravalvular leak 1 (1.3) 1 (2.2) 0 2 (0.7) 1 (0.6) 1 (0.8)
Paravalvular leak plus intra-
prosthetic leak (no haemo-
dynamic consequences)
3 (3.8) 0 3 (9.1) 2 (0.7) 1 (0.6) 1 (0.8)
Permanent pacemaker implant, due
to:
6 (7.7) 3 (6.7) 3 (9.1) 3 (1.1) 1 (0.6) 2 (1.6)
Atrioventricular block (third
degree)
4 (5.1) 3 (6.7) 1 (3.0) 1 (0.4) 0 1 (0.8)
Other reason 2 (2.6) 0 2 (6.1) 2 (0.7) 1 (0.6) 1 (0.8)
a Due to septicaemia
b Due to neoplasia (3 patients) in mitral replacement group, renal failure (1 patient) and non − valve-related death (2 patients) in mitral repair group
c 1 endocarditis, 2 non-structural valve disease
d Non-disabling stroke
e Any bleeding worthy of clinical mention (e.g. access site haematoma) that does not qualify as life-threatening, disabling, or major [19]
f Overt bleeding either associated with a drop in the haemoglobin level of ≥3.0 g/dL or requiring transfusion of 2 or 3 units of whole blood/RBC, or causing
hospitalization or permanent injury, or requiring surgery AND does not meet criteria of life-threatening or disabling bleeding [19]
AE adverse event
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Fig. 2 a Overall survival and b freedom from reintervention in patients who underwent mitral repair or mitral replacement
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complex and high-risk population, but still appeared
shorter than reported for conventional aortic valve re-
placement [7]. Owing to the lack of a matched cohort, it
is difficult to demonstrate a shorter operative time with
the sutureless versus sutured valve.
In the present study, one patient (1.3%) died
within 30 days of the procedure, which compares
with 1.9% in a single-centre experience of 617 pa-
tients using the same sutureless valve [24]. Higher
rates of 30-day death were reported by Hanedan
et al. [7] (5.3% for sutureless AVR and 15.6% for
conventional AVR). Rubino et al. reported a 1.4%
in-hospital mortality rate after an isolated aortic
valve procedure (1.4%), which increased to 7.4%
when performed alongside CABG [13]. Five-year
survival rates were markedly higher in our study
than in Epic [20] (81.3% vs 39.3% with double valve
replacement) whereas bleeding was similar (2.6% vs
2.9% after double valve replacement). Only 1 patient
(1.3%) had a cerebrovascular accident (no strokes
were reported) during the early postoperative
period, compared with 9.1% with double valve re-
placement in Epic [20].
The need for permanent pacemaker implantation re-
mains a concern with the use of sutureless valves, with
postoperative incidence rates of 5% [24] and 10.8% [25].
The rate of permanent pacemaker implantation after
transcatheter AVR with new-generation devices is highly
variable (ranging from 2.3 to 36.1% in a recent systematic
review [26]), and is influenced by electrical, anatomical,
and procedural factors. In the current study, 6 patients
(7.7%) underwent permanent pacemaker implantation
within 30 days of the procedure, 4 due to third-degree
atrioventricular block. By late follow-up, 3 further patients
(1.1% per patient-year) had undergone pacemaker im-
plantation (third-degree atrioventricular block: 0.4% per
patient-year). Our results show a lower rate of pacemaker
implantation compared with the Epic study, which re-
ported an 11.6% rate during hospitalization after double
valve replacement [20]. Our findings are consistent with a
large study of 658 patients, in which the rate of pacemaker
implantation at 1 year for third-degree atrioventricular
block was 9.6% for the sutureless valve [21].
Haemodynamic data – in terms of effective orifice area
and mean and peak aortic pressure gradients – were
good and remained stable through 5 years of follow-up.
Further, the rates of paravalvular leakage were low, com-
prising mild regurgitation with no haemodynamic conse-
quences, and there was no apparent structural valve
deterioration. These findings − consistent with a previ-
ous study in patients undergoing isolated sutureless aor-
tic valve procedures [27] − are reassuring, as the current
labelling for the Perceval sutureless valve includes a pre-
caution about its use in concomitant mitral procedures.
Limitations
This study is limited by the small population size, the
heterogeneous population, the lack of a control group,
and high enrolment at 1 centre.
Conclusion
This study, in high operative risk patients implanted
with a sutureless valve in the presence of a previously
implanted prosthesis in the mitral position or with a
concomitant mitral valve procedure, confirms that the
sutureless implant is a technically feasible procedure
during multivalvular surgery and is associated with good
clinical outcomes.
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